1. [Ibrutinib prescription in B-cell lymphoid neoplasms].
- Author
-
Dougé A, Ravinet A, Bay JO, Tournilhac O, Guièze R, and Lemal R
- Subjects
- Adenine analogs & derivatives, Agammaglobulinaemia Tyrosine Kinase, B-Lymphocytes drug effects, B-Lymphocytes metabolism, Clinical Trials as Topic, Drug Resistance, Neoplasm, France, Humans, Piperidines, Protein Kinase Inhibitors pharmacology, Pyrazoles pharmacology, Pyrimidines pharmacology, Signal Transduction drug effects, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Lymphoma, Mantle-Cell drug therapy, Protein Kinase Inhibitors therapeutic use, Protein-Tyrosine Kinases antagonists & inhibitors, Pyrazoles therapeutic use, Pyrimidines therapeutic use, Waldenstrom Macroglobulinemia drug therapy
- Abstract
Ibrutinib is a new-targeted therapy that irreversibly and specifically inhibits the Bruton's Tyrosine Kinase (BTK), a key component of the signaling pathways of B cells. The results are very encouraging as monotherapy in the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia. Following the results of recent studies, ibrutinib is now available in France for these three diseases., (Copyright © 2015 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF